OXFORD, Engeland–(BUSINESS WIRE)– Exscientia plc (Nasdaq: EXAI) heeft vandaag aangekondigd dat leden van het management zullen deelnemen aan de volgende aanstaande beleggersconferenties in november:

• BofA Securities 2022 A.I. en Disruptive Tech Conference. Fireside-chat (AI in Drug Discovery) op woensdag 9 november 2022 om 12:40 uur. EST (17:40 uur GMT)
• 2022 Jefferies London Healthcare-conferentie. Management neemt deel aan beleggersbijeenkomsten op woensdag 16 november 2022 in Londen, Verenigd Koninkrijk
• 5e jaarlijkse Evercore ISI HealthCONx-conferentie. Fireside-chat op dinsdag 29 november 2022 om 8:50 uur EST (1:50 uur GMT)

Live webcasts van de openhaardchats zullen beschikbaar zijn op de website van het bedrijf, onder de sectie “Investors & Media” op www.investors.exscientia.ai. Gearchiveerde herhalingen van de webcasts zijn ongeveer 30 dagen na de presentatie beschikbaar.

Exscientia to Present at Upcoming Investor Conferences in November

OXFORD, England–(BUSINESS WIRE)– Exscientia plc (Nasdaq: EXAI) today announced that members of management will participate in the following upcoming investor conferences in November:

• BofA Securities 2022 A.I. and Disruptive Tech Conference. Fireside chat (AI in Drug Discovery) on Wednesday, November 9, 2022, at 12:40 p.m. EST (5:40 p.m. GMT)
• 2022 Jefferies London Healthcare Conference. Management will participate in investor meetings on Wednesday, November 16, 2022, in London, United Kingdom
• 5^th Annual Evercore ISI HealthCONx Conference. Fireside chat on Tuesday, November 29, 2022, at 8:50 a.m. EST (1:50 p.m. GMT)

Live webcasts of the fireside chats will be available on the Company’s website, under the “Investors & Media” section at www.investors.exscientia.ai. Archived replays of the webcasts will be available for approximately 30 days following the presentation.

About Exscientia

Exscientia is an AI-driven pharmatech company committed to discovering, designing and developing the best possible drugs in the fastest and most effective manner. Exscientia developed the first-ever functional precision oncology platform to successfully guide treatment selection and improve patient outcomes in a prospective interventional clinical study, as well as to progress AI-designed small molecules into the clinical setting. Our internal pipeline is focused on leveraging our precision medicine platform in oncology, while our partnered pipeline broadens our approach to other therapeutic areas. By pioneering a new approach to medicine creation, we believe the best ideas of science can rapidly become the best medicines for patients.

Exscientia is headquartered in Oxford (England, U.K.), with offices in Vienna (Austria), Dundee (Scotland, U.K.), Boston (Mass., U.S.), Miami (Fla., U.S.), Cambridge (England, U.K.), and Osaka (Japan).

Visit us at https://www.exscientia.ai or follow us on Twitter @exscientiaAI.

View source version on businesswire.com: https://www.businesswire.com/news/home/20221101005278/en/

Contacts

Investors:
Sara Sherman

investors@exscientia.ai

Media:
media@exscientia.ai